Palisade Bio公布PALI-2108治疗纤维狭窄型克罗恩病1B期临床研究积极顶线数据

美股速递
Mar 31

生物制药公司Palisade Bio Inc.近日宣布,其针对纤维狭窄型克罗恩病研发的候选药物PALI-2108,在1B期临床研究中取得了积极的顶线数据结果。

该研究旨在评估PALI-2108的安全性、耐受性及初步疗效信号。数据显示,PALI-2108在试验中表现出良好的耐受性特征,未出现重大安全性问题。同时,药物在关键疗效指标上也显示出令人鼓舞的改善趋势,为后续临床开发提供了有力支持。

这一积极进展标志着Palisade Bio在应对纤维狭窄型克罗恩病这一未满足医疗需求的领域迈出了重要一步。公司计划基于这些数据与监管机构进行沟通,以确定下一步的临床开发策略。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10